The fall of aducanumab…

Throughout the last decade, the drug industry has witnessed the turbulent journey of aducanumab. The controversial approval of this drug in 2021 was preceded by a variety of clinical trials, many exhibiting conflicting findings. Aducanumab is a human monoclonal antibody targeting the protein amyloid-beta, of which large aggregates are often seen during the progression of the neurodegenerative disease Alzheimer’s. There is a wealth of evidence supporting the role of amyloid build up in Alzheimer’s development; however, researchers have struggled to show that this protein is an appropriate target in the treatment of this disease. In other words, it remains unknown...